within Pharmacolibrary.Drugs.ATC.N;

model N03AX26
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 119 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.0141,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Fenfluramine is an amphetamine derivative formerly used as an appetite suppressant for obesity management. It was withdrawn from the market due to concerns about valvular heart disease and pulmonary hypertension. Currently, fenfluramine is approved (under restricted conditions) for adjunctive treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in pediatric patients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=&quot;https://doi.org/10.58347/tml.2024.1708b&quot;>10.58347/tml.2024.1708b</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39073881/&quot;>https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li><li><p>Gammaitoni, A, et al., &amp; Boyd, B (2018). The Lack of Effect of Food on the Pharmacokinetics of ZX008 (Fenfluramine Oral Solution): Results of a Single-dose, Two-period Crossover Study. <i>Clinical therapeutics</i> 40(8) 1338–1346. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2018.05.013&quot;>10.1016/j.clinthera.2018.05.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29941151/&quot;>https://pubmed.ncbi.nlm.nih.gov/29941151</a></p></li><li><p>Mittur, A, et al., &amp; Boyd, B (2024). Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine. <i>Journal of clinical pharmacology</i> 64(7) 887–898. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2431&quot;>10.1002/jcph.2431</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38523492/&quot;>https://pubmed.ncbi.nlm.nih.gov/38523492</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AX26;
